Author: admin

Behcet’s Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Behcet’s Disease pipeline constitutes 4+ key companies continuously working towards developing 4+ Behcet’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Behcet’s Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Behcet’s Disease Market.

 

The Behcet’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Behcet’s Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Behcet’s Disease treatment therapies with a considerable amount of success over the years.

  • Behcet’s Disease companies working in the treatment market are Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others, are developing therapies for the Behcet’s Disease treatment

  • Emerging Behcet’s Disease therapies in the different phases of clinical trials are- SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others are expected to have a significant impact on the Behcet’s Disease market in the coming years.

  • In March 2025, Dr. Christopher J. Schaber, President and CEO of Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical firm developing treatments for rare diseases with high unmet needs, highlighted the company’s dedication to progressing its clinical pipeline. Key upcoming milestones include expected top-line results in 2026 from the ongoing Phase 3 placebo-controlled trial of HyBryte™ (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL). Later this year, Soligenix also plans to release top-line data from its Phase 2 trials of SGX945 (dusquetide) for Behçet’s disease and SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.

  • In November 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with unmet needs, has announced the start of patient enrollment for its Phase 2 clinical trial (protocol DUS-AUBD-01) evaluating SGX945 (dusquetide) as a potential therapy for Behçet’s Disease.

 

Behcet’s Disease Overview

Behçet’s Disease is a rare, chronic inflammatory disorder that causes blood vessel inflammation throughout the body. It can lead to a wide range of symptoms, including mouth and genital ulcers, eye inflammation, skin lesions, joint pain, and, in severe cases, vascular or neurological complications. The exact cause is unknown, but it is considered an autoimmune condition. Treatment typically focuses on controlling inflammation and managing symptoms using medications such as corticosteroids, immunosuppressants, and biologics. Early diagnosis and ongoing management are essential to prevent serious complications and improve quality of life.

 

Get a Free Sample PDF Report to know more about Behcet’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/behcets-disease-pipeline-insight

 

Emerging Behcet’s Disease Drugs Under Different Phases of Clinical Development Include:

  • SGX945: Soligenix

  • RAY121: Chugai Pharmaceutical

  • Dusquetide: Soligenix

  • Filgotinib: UMC Utrecht

  • Hemay005: Ganzhou Hemay Pharmaceutical

  • Apremilast: Amgen

 

Behcet’s Disease Route of Administration

Behcet’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Behcet’s Disease Molecule Type

Behcet’s Disease Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Behcet’s Disease Pipeline Therapeutics Assessment

  • Behcet’s Disease Assessment by Product Type

  • Behcet’s Disease By Stage and Product Type

  • Behcet’s Disease Assessment by Route of Administration

  • Behcet’s Disease By Stage and Route of Administration

  • Behcet’s Disease Assessment by Molecule Type

  • Behcet’s Disease by Stage and Molecule Type

 

DelveInsight’s Behcet’s Disease Report covers around 4+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Behcet’s Disease product details are provided in the report. Download the Behcet’s Disease pipeline report to learn more about the emerging Behcet’s Disease therapies

 

Some of the key companies in the Behcet’s Disease Therapeutics Market include:

Key companies developing therapies for Behcet’s Disease are – Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson (Janssen Korea Ltd.), AbbVie Inc., and others.

 

Behcet’s Disease Pipeline Analysis:

The Behcet’s Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Behcet’s Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Behcet’s Disease Treatment.

  • Behcet’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Behcet’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Behcet’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Behcet’s Disease drugs and therapies

 

Behcet’s Disease Pipeline Market Drivers

  • Rising prevalence of Behçet’s Disease globally

  • Increasing investment in rare disease research and orphan drug development

  • Advancements in biologics and targeted therapies for autoimmune disorders

  • Growing awareness among physicians and patients leading to earlier diagnosis

  • Supportive regulatory frameworks for expedited approval of orphan drugs

 

Behcet’s Disease Pipeline Market Barriers

  • Limited patient population due to rarity of the disease

  • High cost of developing and commercializing novel therapies

  • Challenges in conducting large-scale clinical trials for rare conditions

  • Uncertainties regarding long-term safety and efficacy of emerging treatments

  • Complex regulatory requirements across different regions affecting market entry

 

Scope of Behcet’s Disease Pipeline Drug Insight

  • Coverage: Global

  • Key Behcet’s Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others

  • Key Behcet’s Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others

  • Behcet’s Disease Therapeutic Assessment: Behcet’s Disease current marketed and Behcet’s Disease emerging therapies

  • Behcet’s Disease Market Dynamics: Behcet’s Disease market drivers and Behcet’s Disease market barriers

 

Request for Sample PDF Report for Behcet’s Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Behcet’s Disease Report Introduction

2. Behcet’s Disease Executive Summary

3. Behcet’s Disease Overview

4. Behcet’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Behcet’s Disease Pipeline Therapeutics

6. Behcet’s Disease Late Stage Products (Phase II/III)

7. Behcet’s Disease Mid Stage Products (Phase II)

8. Behcet’s Disease Early Stage Products (Phase I)

9. Behcet’s Disease Preclinical Stage Products

10. Behcet’s Disease Therapeutics Assessment

11. Behcet’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Behcet’s Disease Key Companies

14. Behcet’s Disease Key Products

15. Behcet’s Disease Unmet Needs

16 . Behcet’s Disease Market Drivers and Barriers

17. Behcet’s Disease Future Perspectives and Conclusion

18. Behcet’s Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Behcet’s Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen

Softek Awnings Introduces Premium Retractable Awning for Decks in Atlanta, GA

“Premium Retractable Awning for Decks in Atlanta”
Softek Awnings, the top retractable awning installer in Georgia, is proud to announce the expansion of its premium retractable awning solutions designed specifically for decks and outdoor living spaces. Known for delivering style, durability, and comfort, Softek Awnings helps Atlanta homeowners create functional shade solutions that enhance outdoor enjoyment throughout the year.

August 27, 2025 – Atlanta, GA – With rising demand for customizable outdoor shade, Softek Awnings offers a wide range of retractable awnings for decks, combining modern design with motorized technology for effortless control. These innovative awnings not only provide sun protection but also extend outdoor living areas, increase home value, and improve energy efficiency by reducing heat indoors.

Key Features of Softek Awnings’ Deck Retractable Awnings:

  • Motorized and manual options available

  • Remote-controlled retractable awning systems

  • Heavy-duty, weather-resistant materials

  • Custom sizes to fit any deck or patio

  • Energy-efficient sun protection that lowers cooling costs

  • Wide selection of fabrics and colors to match home exteriors

Atlanta residents seeking to upgrade their decks with reliable retractable awnings will benefit from Softek’s expertise, professional installation, and long-lasting materials designed to withstand Georgia’s climate.

For homeowners ready to transform their outdoor living space, Softek Awnings offers complimentary consultations to help select the ideal retractable awning for decks, tailored to size, functionality, and aesthetic preferences.

To learn more or schedule an appointment, visit Softek Awnings or contact the company directly: https://softekawnings.com/

Media Contact
Company Name: Softek Awnings
Contact Person: Barry Loudis
Email: Send Email
Phone: (678) 904-5637
Address:3641 Clearview Parkway
City: Doraville
State: Georgia
Country: United States
Website: https://softekawnings.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Softek Awnings Introduces Premium Retractable Awning for Decks in Atlanta, GA

Atypical Hemolytic Uremic Syndrome Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Alexion Pharma, Hoffmann-La Roche, Novartis, NovelMed Therapeutics

The Key Atypical Hemolytic Uremic Syndrome Companies in the market include – Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others.

 

The Atypical Hemolytic Uremic Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atypical Hemolytic Uremic Syndrome pipeline products will significantly revolutionize the Atypical Hemolytic Uremic Syndrome market dynamics.

 

DelveInsight’s “Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Atypical Hemolytic Uremic Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Atypical Hemolytic Uremic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atypical Hemolytic Uremic Syndrome Market Insights

 

Some of the key facts of the Atypical Hemolytic Uremic Syndrome Market Report:

  • Atypical Hemolytic Uremic Syndrome market size was highest in United States among the 7MM countries

  • As per Novartis’s Q2 2024 report, the company anticipates datareadout of FABHALTA (NCT04889430, APPELHUS) for the treatment ofaHUS in 2026.

  • In December 2023, A group of five experts from Spain developed consensus guidelines for the management of atypical hemolytic uremic syndrome (aHUS) in adults. These recommendations provide comprehensive guidance throughout the patient’s treatment process, offering support to physicians, particularly those with limited experience, from the initial suspicion of the condition to the commencement and cessation of C5 Therapies.

  • In 2023, the diagnosed cases of atypical hemolytic uremic syndrome (aHUS) in the United States were approximately 2,700. It is expected that these cases will rise during the forecast period from 2024 to 2034.

  • In 2023, there was a higher prevalence of atypical hemolytic uremic syndrome (aHUS) cases in adolescents and adults in the US, with approximately 2,200 cases, compared to the pediatric population, which accounted for around 400 cases. It is anticipated that these numbers will increase by 2034.

  • In 2023, approximately 2,600 cases of atypical hemolytic uremic syndrome (aHUS) were treated in the United States.

  • Key Atypical Hemolytic Uremic Syndrome Companies: Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others

  • Key Atypical Hemolytic Uremic Syndrome Therapies: Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, and others

  • As per the National Organization of Rare Disorders (Nord), the Atypical Hemolytic Uremic Syndrome epidemiology based on gender analyzed that in childhood, Atypical Hemolytic Uremic Syndrome (aHUS) affects males and females in equal numbers

 

Atypical Hemolytic Uremic Syndrome Overview

Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening condition characterized by the formation of blood clots in small blood vessels throughout the body, leading to a triad of symptoms: hemolytic anemia (the destruction of red blood cells), thrombocytopenia (a low platelet count), and acute kidney injury (uremia).

 

Get a Free sample for the Atypical Hemolytic Uremic Syndrome Market Report:

https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market

 

Atypical Hemolytic Uremic Syndrome Market

The dynamics of the Atypical Hemolytic Uremic Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

 

Atypical Hemolytic Uremic Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation:

The Atypical Hemolytic Uremic Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Atypical Hemolytic Uremic Syndrome

  • Prevalent Cases of Atypical Hemolytic Uremic Syndrome by severity

  • Gender-specific Prevalence of Atypical Hemolytic Uremic Syndrome

  • Diagnosed Cases of Episodic and Chronic Atypical Hemolytic Uremic Syndrome

 

Download the report to understand which factors are driving Atypical Hemolytic Uremic Syndrome epidemiology trends @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights

 

Atypical Hemolytic Uremic Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atypical Hemolytic Uremic Syndrome market or expected to get launched during the study period. The analysis covers Atypical Hemolytic Uremic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atypical Hemolytic Uremic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Atypical Hemolytic Uremic Syndrome treatment, visit @ Atypical Hemolytic Uremic Syndrome Medications

 

Atypical Hemolytic Uremic Syndrome Therapies and Key Companies

  • Eculizumab: Alexion Pharmaceuticals

  • Crovalimab: Hoffmann-La Roche

  • Iptacopan: Novartis

  • NM8074: NovelMed Therapeutics

  • Ravulizumab: Alexion Pharmaceuticals

 

Atypical Hemolytic Uremic Syndrome Market Drivers

  • The introduction of eculizumab in the treatment setting significantly improved the prognosis of aHUS patients.

  • The introduction of ravulizumab in the treatment setting led to a significant reduction of treatment burden, as it provided patients with a treatment option with similar efficacy and safety to that of eculizumab but with a far less frequent dosing frequency.

 

Atypical Hemolytic Uremic Syndrome Market Barriers

  • The successful launch of iptacopan could significantly improve treatment convenience, as it would bring an oral route of treatment administration in a disease that potentially requires lifelong treatment.

  • Currently, there are limited treatment options for aHUS. Moreover, only a few emerging drugs are active in the pipeline. Thus, it allows pharma players to introduce a novel product candidate into the aHUS market, which can change the therapeutic market scenario.

 

Scope of the Atypical Hemolytic Uremic Syndrome Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Atypical Hemolytic Uremic Syndrome Companies: Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others

  • Key Atypical Hemolytic Uremic Syndrome Therapies: Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, and others

  • Atypical Hemolytic Uremic Syndrome Therapeutic Assessment: Atypical Hemolytic Uremic Syndrome current marketed and Atypical Hemolytic Uremic Syndrome emerging therapies

  • Atypical Hemolytic Uremic Syndrome Market Dynamics: Atypical Hemolytic Uremic Syndrome market drivers and Atypical Hemolytic Uremic Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Atypical Hemolytic Uremic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Atypical Hemolytic Uremic Syndrome Market Access and Reimbursement

 

Discover more about therapies set to grab major Atypical Hemolytic Uremic Syndrome market share @ Atypical Hemolytic Uremic Syndrome Treatment Landscape

 

Table of Contents

1. Atypical Hemolytic Uremic Syndrome Market Report Introduction

2. Executive Summary for Atypical Hemolytic Uremic Syndrome

3. SWOT analysis of Atypical Hemolytic Uremic Syndrome

4. Atypical Hemolytic Uremic Syndrome Patient Share (%) Overview at a Glance

5. Atypical Hemolytic Uremic Syndrome Market Overview at a Glance

6. Atypical Hemolytic Uremic Syndrome Disease Background and Overview

7. Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Atypical Hemolytic Uremic Syndrome

9. Atypical Hemolytic Uremic Syndrome Current Treatment and Medical Practices

10. Atypical Hemolytic Uremic Syndrome Unmet Needs

11. Atypical Hemolytic Uremic Syndrome Emerging Therapies

12. Atypical Hemolytic Uremic Syndrome Market Outlook

13. Country-Wise Atypical Hemolytic Uremic Syndrome Market Analysis (2020–2034)

14. Atypical Hemolytic Uremic Syndrome Market Access and Reimbursement of Therapies

15. Atypical Hemolytic Uremic Syndrome Market Drivers

16. Atypical Hemolytic Uremic Syndrome Market Barriers

17. Atypical Hemolytic Uremic Syndrome Appendix

18. Atypical Hemolytic Uremic Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atypical Hemolytic Uremic Syndrome Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Alexion Pharma, Hoffmann-La Roche, Novartis, NovelMed Therapeutics

Bronchiectasis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsight | SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Bronchiectasis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchiectasis Market.

 

The Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Bronchiectasis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Bronchiectasis treatment therapies with a considerable amount of success over the years.

  • Bronchiectasis companies working in the treatment market are SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Bronchiectasis treatment

  • Emerging Bronchiectasis therapies in the different phases of clinical trials are- S1226, Brensocatib, P339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Bronchiectasis market in the coming years.

  • In August 2025, The FDA has approved brensocatib (Brinsupri; Insmed) for the treatment of non–cystic fibrosis bronchiectasis, marking it as the first approved therapy for this patient group and the first dipeptidyl peptidase 1 (DPP1) inhibitor authorized for a neutrophil-driven disease. Brensocatib is an oral, small-molecule, reversible DPP1 inhibitor that blocks DPP1, reducing the activation of neutrophil serine proteases, which play a central role in inflammation and tissue damage in chronic lung diseases such as bronchiectasis.

  • In February 2025, The FDA assigned priority review to brensocatib, an investigational therapy for patients with non-cystic fibrosis bronchiectasis. After the new drug application was accepted, the target action date was scheduled for August 12, 2025. If approved, brensocatib would be the first approved treatment for bronchiectasis and the inaugural drug in the dipeptidyl peptidase 1 class for neutrophil-driven diseases.

  • In February 2025, Verona Pharma is a biopharmaceutical company focused on creating and commercializing innovative therapies for chronic respiratory diseases with significant unmet needs. Its first commercial product, Ohtuvayre™ (ensifentrine), is the first inhaled maintenance therapy for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ensifentrine also holds promise for treating non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory disorders.

 

Bronchiectasis Overview

Bronchiectasis is a chronic lung condition characterized by permanent widening and damage of the airways (bronchi), leading to mucus buildup, frequent lung infections, coughing, and difficulty breathing. It often results from infections, genetic disorders like cystic fibrosis, or conditions that impair the lungs’ ability to clear mucus. Early management can help reduce complications and improve quality of life.

 

Get a Free Sample PDF Report to know more about Bronchiectasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bronchiectasis-pipeline-insight

 

Emerging Bronchiectasis Drugs Under Different Phases of Clinical Development Include:

  • S1226: SolAeroMed

  • Brensocatib: Insmed

  • NP339: NovaBiotics Ltd

  • Research Programme:NCFB: Synspira Therapeutics

  • Research programme: mucolytic agents: Parion Sciences

  • CHF 6333: Chiesi Farmaceutic

  • CSL787: CSL Behring

  • HSK31858: Haisco Pharmaceutical

  • S-1226: SolAeroMed Inc.

  • Benralizumab: AstraZeneca

  • Colistimethate sodium: Zambon SpA

  • BI 1291583: Boehringer Ingelheim

  • AP-PA02: Armata Pharmaceuticals

  • ARINA-1: Renovion

 

Bronchiectasis Route of Administration

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Bronchiectasis Molecule Type

Bronchiectasis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Bronchiectasis Pipeline Therapeutics Assessment

  • Bronchiectasis Assessment by Product Type

  • Bronchiectasis By Stage and Product Type

  • Bronchiectasis Assessment by Route of Administration

  • Bronchiectasis By Stage and Route of Administration

  • Bronchiectasis Assessment by Molecule Type

  • Bronchiectasis by Stage and Molecule Type

 

DelveInsight’s Bronchiectasis Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Bronchiectasis product details are provided in the report. Download the Bronchiectasis pipeline report to learn more about the emerging Bronchiectasis therapies

 

Some of the key companies in the Bronchiectasis Therapeutics Market include:

Key companies developing therapies for Bronchiectasis are – Zambon, Boehringer Ingelheim, SolAeroMed, Insmed Incorporated, Chiesi Farmaceutici, Renovion, Haisco Pharmaceutical, Armata Pharmaceuticals, AstraZeneca, CSL Behring, and others.

 

Bronchiectasis Pipeline Analysis:

The Bronchiectasis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.

  • Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Bronchiectasis drugs and therapies

 

Bronchiectasis Pipeline Market Drivers

  • Increasing prevalence of bronchiectasis worldwide, particularly among aging populations

  • Rising awareness and improved diagnosis of the disease

  • Advancements in novel therapies targeting underlying causes and inflammation

  • Growing investment in research and development by pharmaceutical companies

  • Expansion of clinical trials exploring innovative drug candidates

 

Bronchiectasis Pipeline Market Barriers

  • High costs associated with drug development and clinical trials

  • Complexity of the disease with heterogeneous patient populations

  • Limited efficacy of some current therapeutic options in advanced cases

  • Stringent regulatory requirements for approval of new treatments

  • Challenges in patient recruitment for clinical trials

 

Scope of Bronchiectasis Pipeline Drug Insight

  • Coverage: Global

  • Key Bronchiectasis Companies: SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others

  • Key Bronchiectasis Therapies: S1226, Brensocatib, P339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others

  • Bronchiectasis Therapeutic Assessment: Bronchiectasis current marketed and Bronchiectasis emerging therapies

  • Bronchiectasis Market Dynamics: Bronchiectasis market drivers and Bronchiectasis market barriers

 

Request for Sample PDF Report for Bronchiectasis Pipeline Assessment and clinical trials

 

Table of Contents

1. Bronchiectasis Report Introduction

2. Bronchiectasis Executive Summary

3. Bronchiectasis Overview

4. Bronchiectasis- Analytical Perspective In-depth Commercial Assessment

5. Bronchiectasis Pipeline Therapeutics

6. Bronchiectasis Late Stage Products (Phase II/III)

7. Bronchiectasis Mid Stage Products (Phase II)

8. Bronchiectasis Early Stage Products (Phase I)

9. Bronchiectasis Preclinical Stage Products

10. Bronchiectasis Therapeutics Assessment

11. Bronchiectasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bronchiectasis Key Companies

14. Bronchiectasis Key Products

15. Bronchiectasis Unmet Needs

16 . Bronchiectasis Market Drivers and Barriers

17. Bronchiectasis Future Perspectives and Conclusion

18. Bronchiectasis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchiectasis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsight | SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion

AV Access Introduces iDock M10: A 4K Dual Monitor KVM Docking Station Designed for MacBook Users

““AV Access is proud to introduce the iDock M10 4K KVM switch docking station, designed to meet the needs of MacBook users in video editing, graphic design, and gaming. As demand for multi-PC and multi-monitor setups grows, this innovative device enables users to efficiently manage a MacBook, desktop, dual monitors, and multiple USB peripherals with ease,” explained Bill Liao, CTO of AV Access.”
AV Access unveils the iDock M10, an advanced 4K KVM switch combined with a 10-in-1 docking station—purpose-built for MacBook users. This compact solution allows users to seamlessly control both a Mac laptop and a desktop on a dual-monitor setup, while connecting multiple peripherals—all from a single workstation. Whether for work, study, or gaming, the iDock M10 boosts productivity and simplifies setup.

AV Access, a global leader in Pro AV and AV over IP solutions, proudly announces the release of the iDock M10 4K USB-C KVM docking station. Specifically engineered for the macOS ecosystem, the iDock M10 offers true dual-monitor support for MacBook, overcoming system limitations that typically restrict extended displays via a single USB-C connection. With dual USB-C inputs, up to 100W charging, and 10Gbps data transfer, it delivers high-performance connectivity for professional-grade multitasking.

USB-C KVM Docking Station Built Around MacBook Needs

“Mac laptops are known for streamlined design—but that often comes with port limitations. For MacBook users needing two external monitors, seamless switching between devices, and clutter-free peripheral access, the iDock M10 delivers the missing piece,” explained Bill Liao, CTO of AV Access.

With two USB-C inputs and a combined HDMI + DP + USB interface group, users can connect both a MacBook and a desktop PC to the same setup. The iDock M10 supports essential peripherals like keyboards, mice, external drives, headphones, and SD cards—all through USB 3.0, USB-C, Ethernet, HDMI outputs, audio jack, and more. It consolidates connections and reduces cable chaos, turning complex dual-computer workflows into a smooth experience.

Seamless Switching for Work and Play

Designed for hybrid work and gaming scenarios, the iDock M10 lets users toggle between a MacBook and desktop at the push of a button or via a wired remote controller. Its robust spec sheet includes support for 4K video input, fast data transmission up to 10Gbps, and Gigabit LAN access for both connected systems.

Gamers will appreciate the support for high refresh rates like 2560×1440@144Hz/120Hz and 1080P@240Hz/165Hz, ensuring fluid performance for fast-paced visuals. Whether switching between video editing and gameplay or collaborating remotely, the iDock M10 provides a responsive, uninterrupted experience.

The iDock M10 is now available on AV Access’s official site at $269.99. It joins a lineup of iDock series solutions, including the iDock C10, iDock B10, and iDock C20, designed for seamless switching between work and gaming environments.

About AV Access

AV Access is a global leader in Pro AV and AV over IP solutions, offering a diverse range of products, including HDMI/KVM extenders, splitters, switchers, KVM switches, AV over IP solutions, and wireless conferencing systems. Since its inception, the company has been committed to delivering high-quality AV products at competitive pricing, providing seamless audiovisual experiences for users worldwide.

AV Access continues to innovate, developing cutting-edge solutions for smart home, corporate, education, retail, entertainment, healthcare, and more. Backed by a strong R&D team, a robust supply chain, and an expert management team, AV Access is a trusted partner in AV technology. Learn more at www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Introduces iDock M10: A 4K Dual Monitor KVM Docking Station Designed for MacBook Users

Anticoagulants Market Positioned for Accelerated Development Through 2032, DelveInsight Finds | Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires

The Key Anticoagulants Companies in the market include – Universitaire Ziekenhuizen KU Leuven, Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires, and others.

 

DelveInsight’s “Anticoagulants Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Anticoagulants, historical and forecasted epidemiology as well as the Anticoagulants market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Anticoagulants, offering comprehensive insights into the Anticoagulants revenue trends, prevalence, and treatment landscape. The report delves into key Anticoagulants statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anticoagulants therapies. Additionally, we cover the landscape of Anticoagulants clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anticoagulants treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anticoagulants space.

 

To Know in detail about the Anticoagulants market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anticoagulants Market Forecast

 

Some of the key facts of the Anticoagulants Market Report:

  • The Anticoagulants market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In November 2024, Boston Scientific Corporation (NYSE: BSX) announced favorable three-year primary endpoint results from the global OPTION clinical trial evaluating the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. The study compared the device to first-line oral anticoagulation (OAC) treatments—including direct oral anticoagulants (DOACs) at 95% and warfarin at 5%—for reducing stroke risk in patients with non-valvular atrial fibrillation after cardiac ablation. These key findings were shared during a late-breaking science session at the American Heart Association’s Scientific Sessions.

  • Key Anticoagulants Companies: Universitaire Ziekenhuizen KU Leuven, Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires, and others

  • Key Anticoagulants Therapies: apixaban, Long DOAC, PPSB-SD, ATI-5923, Enoxaparin, and others

  • The Anticoagulants market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anticoagulants pipeline products will significantly revolutionize the Anticoagulants market dynamics.

  • High global burden of thromboembolic disorders: Conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE) affect millions annually worldwide

  • Atrial fibrillation (AF) prevalence: Over 37 million people globally suffer from AF, a major risk factor requiring anticoagulant therapy

  • Rising incidence of stroke: About 15 million people suffer strokes each year, with ischemic stroke often needing anticoagulant treatment

  • Elderly population at higher risk: Individuals aged 65 and above are the most frequent users of anticoagulants due to increased clotting risk

  • Cancer-associated thrombosis (CAT): Patients with cancer have a 4–7 times higher risk of venous thromboembolism, requiring anticoagulant management

 

Anticoagulants Overview

Anticoagulants are medications that help prevent blood clots from forming or growing larger. They are often referred to as “blood thinners,” although they don’t actually thin the blood. Instead, they work by interfering with the body’s natural clotting process. Anticoagulants are commonly used to reduce the risk of stroke, heart attack, deep vein thrombosis (DVT), and pulmonary embolism (PE). Common types include warfarin, heparin, and direct oral anticoagulants (DOACs) like apixaban and rivaroxaban. While effective, they must be used carefully due to the increased risk of bleeding.

 

Get a Free sample for the Anticoagulants Market Forecast, Size & Share Analysis Report:

qhttps://www.delveinsight.com/report-store/anticoagulants-market

 

Anticoagulants Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Anticoagulants Epidemiology Segmentation:

The Anticoagulants market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Anticoagulants

  • Prevalent Cases of Anticoagulants by severity

  • Gender-specific Prevalence of Anticoagulants

  • Diagnosed Cases of Episodic and Chronic Anticoagulants

 

Download the report to understand which factors are driving Anticoagulants epidemiology trends @ Anticoagulants Epidemiology Forecast

 

Anticoagulants Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anticoagulants market or expected to get launched during the study period. The analysis covers Anticoagulants market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anticoagulants Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Anticoagulants Therapies and Key Companies

  • apixaban: Universitaire Ziekenhuizen KU Leuven

  • Long DOAC: Takeshi Morimoto

  • PPSB-SD: Prothya BioSolutions

  • ATI-5923: ARYx Therapeutics

  • Enoxaparin: Les Laboratoires

 

Discover more about therapies set to grab major Anticoagulants market share @ Anticoagulants Treatment Landscape

 

Anticoagulants Market Drivers

  • Rising prevalence of cardiovascular diseases

  • Growing aging population

  • Advancements in drug formulations

  • Increased awareness

  • Government initiatives

 

Anticoagulants Market Barriers

  • Risk of bleeding complications

  • High cost of newer therapies

  • Stringent regulatory requirements

  • Lack of awareness in developing regions

  • Drug interactions

 

Scope of the Anticoagulants Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Anticoagulants Companies: Universitaire Ziekenhuizen KU Leuven, Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires, and others

  • Key Anticoagulants Therapies: apixaban, Long DOAC, PPSB-SD, ATI-5923, Enoxaparin, and others

  • Anticoagulants Therapeutic Assessment: Anticoagulants current marketed and Anticoagulants emerging therapies

  • Anticoagulants Market Dynamics: Anticoagulants market drivers and Anticoagulants market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Anticoagulants Unmet Needs, KOL’s views, Analyst’s views, Anticoagulants Market Access and Reimbursement

 

To know more about Anticoagulants companies working in the treatment market, visit @ Anticoagulants Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Anticoagulants Market Report Introduction

2. Executive Summary for Anticoagulants

3. SWOT analysis of Anticoagulants

4. Anticoagulants Patient Share (%) Overview at a Glance

5. Anticoagulants Market Overview at a Glance

6. Anticoagulants Disease Background and Overview

7. Anticoagulants Epidemiology and Patient Population

8. Country-Specific Patient Population of Anticoagulants

9. Anticoagulants Current Treatment and Medical Practices

10. Anticoagulants Unmet Needs

11. Anticoagulants Emerging Therapies

12. Anticoagulants Market Outlook

13. Country-Wise Anticoagulants Market Analysis (2019–2032)

14. Anticoagulants Market Access and Reimbursement of Therapies

15. Anticoagulants Market Drivers

16. Anticoagulants Market Barriers

17. Anticoagulants Appendix

18. Anticoagulants Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticoagulants Market Positioned for Accelerated Development Through 2032, DelveInsight Finds | Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires

Scent Squad Launches in Toronto, Blending Middle Eastern Perfumery Heritage with North American Preferences

Toronto, ON – August 26, 2025 – Scent Squad, a Toronto-based fragrance house, has officially launched with an artisanal collection of long-lasting perfumes that bridge the rich traditions of Middle Eastern perfumery and contemporary North American tastes. Founded by Shuaib, a third-generation perfumer, and Arslan, a business strategist and entrepreneur, the brand brings together deep-rooted craftsmanship and market insight into a fragrance house defined by heritage and innovation.

Image of Shuaib mixing perfumes

With roots in Dubai, Shuaib grew up learning the craft directly from his father. His family heritage instilled a respect for natural ingredients and a belief that fragrances should be both powerful and accessible. It is this balance of tradition and reinvention that Shuaib describes as the heart of Scent Squad.

“My journey began in Dubai, where perfume was as much heritage as it was artistry,” said Shuaib. “With Scent Squad, we saw an opportunity to connect cultures, making fragrances that are rich, long-lasting, but also lighter and more adaptable. It’s about honoring where we come from while embracing North American preferences.”

Scent Squad’s debut collection showcases this philosophy with four fragrances that highlight the fusion of tradition and modern taste:

  • Arabian Nights: A beloved Middle Eastern classic refined with a lighter touch for Western sensibilities.

  • Rose Royale: A feminine blend of vanilla, aged agarwood, jasmine, pineapple, and rose.

  • Ocean Breeze: A fresh, airy combination of sea salt, sage, and grapefruit.

  • Oud Elixir: A poetic fusion of rose and woods, carrying Middle Eastern depth with French-inspired elegance.

Scent Squad fragrances are made in Canada. They combine fair-trade sourced oud, resins, and essential oils from the Middle East with locally resonant notes like Canadian cedarwood and floral accords. Each blend avoids synthetic dyes, phthalates, and parabens, ensuring formulations that are skin friendly and designed to minimize common sensitivities sometimes associated with chemical additives in mass-market fragrances.

Beyond its product line, Scent Squad is also building a growing online community through social media education, live demonstrations, and behind-the-scenes storytelling about the art of perfumery.

The launch positions Scent Squad as a bold new voice in the North American fragrance market, one that’s committed to cultural authenticity, natural ingredients, and designs that bridge global traditions.

To learn more about Scent Squad and explore its signature collections, please visit https://www.scentsquad.ca/.

Socials: @scentsquad.ca

Media Contact
Company Name: Scent Squad
Contact Person: Mr. Shuaib Hasan
Email: sales@scentsquad.ca
Phone: (437) 473-7247
Country: Canada
Website: https://www.scentsquad.ca/

NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence

NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,” said Anil R. Diwan, Ph.D., President and Chairman, adding, “NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.

For years, doctors have known that viral infections can cause inflammation, but recent studies have revealed a more alarming connection: viruses may reawaken “sleeping” cancer cells, leading to a resurgence of metastatic cancer. Now, a clinical-stage drug candidate, NV-387, is showing promise in fighting both viral infections and the inflammation that could trigger cancer’s return.

The Unseen Threat of Viral Infections

Recent research has shed light on how viruses, particularly those like SARS-CoV-2 (COVID-19) and Influenza, can increase the risk of metastatic cancer recurrence. Viral infections cause a significant inflammatory response, marked by an increase in cytokines like IL-6. This heightened inflammation can stir dormant cancer cells from their “slumber,” allowing them to spread to new parts of the body. This discovery highlights an unmet medical need: a treatment that can not only neutralize the virus but also calm the inflammatory storm it creates.

NV-387: A Dual-Action Solution

Developed by NanoViricides, Inc., (NYSE: NNVC) NV-387 is a unique antiviral drug designed to address both sides of this threat. Its mechanism of action is two-fold:

  1. Direct Antiviral Action: The drug attacks the virus itself, preventing it from replicating and causing illness. In animal model studies, NV-387 has proven effective against a range of lethal respiratory viruses, including Influenza, RSV, and even coronaviruses. In one study, it protected the lungs of animals with severe Influenza A/H3N2 infection, outperforming existing approved drugs like Tamiflu and Xofluza.

  2. Anti-Inflammatory Effect: A key finding is that NV-387 treatment significantly reduces inflammatory markers, including IL-6. By taming the body’s immune response, the drug may minimize the risk of reactivating dormant cancer cells, offering a potential new line of defense for cancer patients in remission who contract a viral infection.

This dual-action capability positions NV-387 as a potential breakthrough in managing viral infections, especially for vulnerable populations where the stakes are higher than a simple cold or flu.

Answering an Unmet Medical Need

The world faces a constant barrage of viral threats, from the two annual waves of COVID-19 to the seasonal resurgence of Influenza and RSV. Traditional defenses like vaccines and antibodies often struggle to keep up with new variants, leaving a gap in our medical arsenal.

NV-387’s broad-spectrum nature means viruses may be unable to escape it, a significant advantage over other treatments. The drug’s ability to protect the lungs and reduce inflammation has been demonstrated in multiple animal studies, paving the way for its progression into Phase II clinical trials. If successful, NV-387 could become an essential tool not just for treating viral illnesses but also for protecting cancer patients from the devastating possibility of a cancer recurrence triggered by a simple viral infection. Other notable biotech stocks to keep an eye out include Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) and Legend Biotech Corporation (NASDAQ: LEGN). VKTX and REGN have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter has declined 17%. Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) announced today that they will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 4:05 p.m. ET.

Sources:

https://finance.yahoo.com/news/drug-could-reduce-metastatic-cancer-123000404.html

https://finance.yahoo.com/news/legend-biotech-participate-morgan-stanley-120000442.html

https://finance.yahoo.com/news/2-biotech-stocks-could-soar-124500482.html

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://UsaStockReport.com//disclaimer/. https://UsaStockReport.com/ has been compensated one thousand dollars by a 3rd party EDM Media for content distribution services on NNVC for August 27, 2025. https://UsaStockReport.com/ is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of https://UsaStockReport.com/ is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results. https://UsaStockReport.com/ does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading. https://UsaStockReport.com/ is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by https://UsaStockReport.com/ or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. https://UsaStockReport.com/ is not a fiduciary by virtue of any person’s use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.

Media Contact
Company Name: UsaStockReport
Contact Person: Ash K
Email: editor@usastockreport.com
City: Frisco
State: Texas
Country: United States
Website: https://usastockreport.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence

Smart Stadiums Market Top Business Strategy, Leading Companies, Growth Factors, Healthy CAGR, Opportunities & Forecast – 2029

“Cisco (US), IBM (US), Ericsson (Sweden), Johnson Controls (Ireland), Schneider Electric (France), NEC (Japan), Huawei (China), Intel (US), Fujitsu (Japan), NTT Corporation (Japan), Honeywell (US), Extreme Networks (US), Infosys (India), Lumen Technologies (US), NXP Semiconductors (Netherlands), VIX Technology (Australia), Hawk-eye (UK), Atos (France), Verizon (US).”
Smart Stadiums Market by Solutions (Digital Content Management, Stadium and Public Security, Building Automation, Event Management, Network Management, and Crowd Management), Stadium Type (Indoor, Outdoor, and Multi-Purpose) – Global Forecast to 2029.

The size of the global Smart Stadiums Market is expected to increase at a Compound Annual Growth Rate (CAGR) of 16.4%, from USD 19.55 billion in 2024 to USD 41.68 billion by 2029. The market for smart stadiums is expanding due to the fast rising fan demand for more engaging experiences via connected technology. Conventional stadiums lacked digital interactivity and had simple setups, thus they missed out on real-time information and visitor-specific features. Stadiums have been transformed into connected venues that improve operations, ensure public safety, and engage fans in recent years thanks to IoT AI and 5G. The usage of the newest technologies in stadiums has been driven by factors including the increase in international sporting events and the demand for improved facilities.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137092340

“By Solution type, Digital Content Management is expected to hold a highest growth rate during the forecast period.”

Digital content management holds the highest growth in the Smart Stadiums market during the forecast period because it is the most central role in enhancing fan engagement and experience. This solution includes audio and video content, digital signage, mobile and web content, which help to deliver real-time updates, instant replays, as well as interactive content to the fans. The demand for more personalized and immersive experiences leads to the adoption of digital content management systems. The growing use of mobile devices and high-speed internet will also further propel growth in seamless content delivery. Furthermore, effective monetization through targeted advertising and exclusive digital offerings would also have a considerable impact in further driving its rapid expansion. With the objective of stadiums to attain a better, more connected environment for spectators, digital content management appears as an important aspect sufficient enough for driving strong growth in the Smart Stadiums market.

“Based on Event Management Solution segment , the Ticketing Management solution will hold the largest market size during the forecast period.”

Ticketing management solutions are anticipated to capture the largest market size in the sector of Smart Stadiums during the forecast period. This is primarily due to the growing requirements for smooth and seamless ticketing processes. The Smart Stadiums are taking up digital ticketing through the mobile applications thereby, leading to an increased facility to switch, purchase, and validate tickets as opposed to printed tickets, thus minimizing waiting time in case of entrance to the grounds. For instance, during matches such as the UEFA Champions League, hundreds of thousands can gain admission to the stadium grounds without any complication, which means better services for fans. In addition, it offers attendance and preference statistics, which allows the managers to optimize the seating and tailor marketing programs. The convenience and efficiency offered by these ticketing management solutions are key factors driving their dominance in the market.

“By Solution type, Stadium and Public Security is expected to hold the highest market share during the forecast period.”

Stadium and public security solutions are expected to maintain the highest market share in the Smart Stadiums market during the forecast period because stadium and public security solutions are essential for ensuring the safety and security of visitors, staff, and players. These solutions include advanced surveillance systems, facial recognition, biometric scanning, and metal detection, which are especially crucial for avoiding unauthorized access and controlling crowd surges. Increasing the number of mass events demands strong security measures. In addition, utilizing AI and IoT technologies will improve real-time monitoring and threat detection capabilities, and these solutions have become essential to modern stadiums. It ensures a safe environment and boosts fan confidence and overall event experience, all of which contribute to the higher market share for stadium and public security solutions.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=137092340

Unique Features in the Smart Stadiums Market

Smart stadiums are uniquely designed to elevate fan engagement by integrating mobile applications, high-speed Wi-Fi, AR/VR experiences, and personalized digital content delivery. Features like mobile ticketing, cashless payments, and real-time navigation ensure convenience and a seamless journey for spectators, making the entire stadium experience more interactive and immersive.

One of the distinguishing features of the smart stadiums market is the extensive use of IoT sensors, connected devices, and AI-driven platforms for real-time monitoring. From crowd management to seat occupancy tracking, IoT ensures efficient stadium operations. Smart connectivity also helps in providing personalized advertisements and services based on fan behavior and preferences.

Smart stadiums leverage biometric access control, AI-powered surveillance, facial recognition, and predictive threat detection to ensure safety. Integrated security systems not only monitor crowd behavior but also help authorities take preventive actions against potential risks, ensuring a safe environment for fans and staff.

A unique feature of smart stadiums is their emphasis on green technologies. With smart lighting, renewable energy integration, automated HVAC systems, and intelligent waste management, stadiums significantly reduce their carbon footprint. Sustainability has become a central differentiator for modern venues, appealing to both sports organizations and eco-conscious audiences.

Major Highlights of the Smart Stadiums Market

One of the major highlights of the smart stadiums market is the growing emphasis on providing fans with a connected, engaging, and personalized experience. Stadium operators are increasingly investing in digital solutions such as mobile apps, AR/VR technologies, and real-time content streaming to attract and retain audiences.

The market is witnessing rapid adoption of IoT sensors, AI-driven analytics, and 5G networks to enable real-time data processing and seamless connectivity. These technologies play a crucial role in improving operational efficiency, crowd management, predictive maintenance, and delivering next-level digital fan services.

Security remains a top priority, with smart stadiums implementing advanced surveillance systems, biometric access control, facial recognition, and emergency response solutions. These measures ensure a safer environment for spectators, athletes, and staff, reducing risks associated with large gatherings.

Sustainability initiatives are a major highlight, with smart stadiums deploying smart lighting, renewable energy integration, water conservation systems, and automated HVAC solutions. These eco-friendly strategies not only lower operating costs but also align with global efforts toward carbon neutrality.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=137092340

Top Companies in the Smart Stadiums Market

Various globally established players, such as Cisco (US), IBM (US), Ericsson (Sweden), Johnson Controls (Ireland), and Schneider Electric (France), are dominating the Smart Stadiums market. To increase their market share, these competitors have used various growth methods, including partnerships, agreements, collaborations, new product releases, product enhancements, and acquisitions.

Cisco Systems

Cisco Systems (Cisco) is one of the global leaders known for integrating technologies across various domains, focusing on networks, security, collaboration tools, applications, cloud services, Internet of Things, and data centers.. It offers Smart Stadiums solutions through its network branch. Cisco’s Connected Stadium Solution is designed to boost fan experience and make sports venues operate more efficiently. This solution includes dense Wi-Fi video watching, tools for staff to work together, ways to study how fans act, and gadgets that link up with the IoT, among other features. Cisco’s full range of products helps turn traditional stadiums into high-tech venues that address the rising expectations of the fans. Cisco’s Smart Stadium solution enhances fan experiences and optimizes operations through advanced networking, IoT integration, and analytics. It also provides high-density Wi-Fi and real-time data insights, thereby improving connectivity and enabling personalized services in stadiums. Cisco’s most recent financial statement shows the company brought in USD 57.00 billion in sales last year. As of September 2024, Cisco has about 100,000 employees around the globe. The company has set up shop and does business in North America, Europe, Asia, Latin America, and the Middle East and Africa.

IBM

IBM is another prominent entity in the smart stadium domain. BY leveraging its expertise in cloud computing, artificial intelligence, and IoT solutions, the company provides advanced technologies that enable stadium operators to enhance fan experiences, improve operational efficiency, and strengthen security measures. IBM operates through its technology business, namely, software, consulting, infrastructure, and financing. Its products include analytics, cloud, cognitive, commerce, loT, industry solutions, systems, mobile, security, and social platforms. IBM’s smart stadium solutions offer real-time data analytics, crowd management, and seamless connectivity, enabling venues to transform into digital ecosystem. These solutions include IBM Watsonx, IBM Storage, and IBM Maximo- the IBM Cloud Ecosystem. These tools boost fan engagement, make operations more efficient, and let users track energy use and crowd levels in real time marking a big step forward in the Smart Stadiums field. IBM Cloud also scales up data analysis, while AI-powered fan engagement tools like mobile ticketing and custom services team up to improve the fan experience. IBM’s cutting-edge smart security uses AI-driven surveillance and predictive analysis to keep stadiums safe. In 2023, IBM brought in USD 61.9 billion in revenue. That same year, IBM had 282,000 employees around the world. The company operates across five continents, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Ericsson (Sweden)

Ericsson is a global leader in telecommunications and networking, playing a pivotal role in the smart stadiums market by providing advanced connectivity solutions. Leveraging 5G technology, Ericsson enables seamless, high-speed internet and enhanced fan experiences through real-time data analytics, augmented reality (AR), and smart facility management systems.

Johnson Controls (Ireland)

Johnson Controls specializes in building automation and energy efficiency solutions, contributing to smart stadiums with integrated systems for HVAC, lighting, and security. Their focus on sustainability and intelligent building management helps stadiums optimize operations, reduce energy consumption, and enhance visitor comfort.

Schneider Electric (France)

Schneider Electric brings expertise in energy management and automation to the smart stadiums market. Their solutions focus on sustainable energy practices, including microgrids, smart lighting, and power distribution, ensuring efficient energy use while supporting stadiums’ operational resilience and environmental goals.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/smart-stadium-market-137092340.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Stadiums Market Top Business Strategy, Leading Companies, Growth Factors, Healthy CAGR, Opportunities & Forecast – 2029

Transportation Management System Market Growth Drivers, Emerging Trends, Opportunities, Key Segments, Recent Development, and Future Outlook To 2030

“Oracle (US), SAP (Germany), Manhattan Associates (US), C.H. Robinson (US), Trimble (US), Wisetech Global (Australia), Descartes (Canada), Generix Group (France), Körber AG (Germany), Blue Yonder (US).”
Transportation Management System Market by Solutions (Planning & Execution, Order Management, Analytics & Reporting, Routing & Tracking), Transportation Mode (Roadways, Railways, Airways, Maritime), and End User – Global Forecast to 2030.

The Transportation Management System Market is expected to increase at a 14.9% compound annual growth rate (CAGR) from USD 18,503.2 million in 2025 to USD 37,036.8 million by 2030. For many businesses, transportation represents a substantial cost component. Through real-time tracking, load consolidation, and route optimization, TMS technologies assist in lowering these expenses. TMS reduces needless mileage and fuel usage by making sure that cars travel the most economical routes and are completely loaded. Additionally, proactive problem-solving and real-time tracking reduce delays and improve the dependability of transportation services, which lowers costs and boosts operational effectiveness and propels the market for transportation management systems.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232446179

Environmental sustainability is becoming increasingly important for businesses and consumers. Governments are implementing stricter regulations to reduce carbon emissions, and companies are setting ambitious sustainability goals. TMS solutions support these efforts by optimizing routes to reduce fuel consumption, integrating electric and alternative fuel vehicles, and providing analytics to monitor and report on environmental impact. These capabilities assist businesses in reducing their carbon footprint and complying with regulations while potentially lowering costs related to fuel and emissions, thereby driving the market.

Freight forwarders end user segment is projected to register the highest CAGR during the forecast period

The freight forwarders end user segment in the transportation management system (TMS) market is poised to achieve the highest CAGR due to the rapid digitization of global logistics and a surge in international trade volumes. Freight forwarders are increasingly leveraging advanced TMS solutions to automate complex logistics processes, manage multi-modal shipments, and gain real-time end-to-end supply chain visibility. The expansion of e-commerce alongside rising customer expectations for seamless, rapid delivery is fueling demand for predictive analytics, AI-powered route optimization, and instant shipment tracking.

New developments include the integration of TMS platforms with enterprise resource planning (ERP), warehouse management systems (WMS), and IoT technologies, enabling greater operational efficiency and data-driven decision-making. Additionally, the focus on sustainability and regulatory compliance has led to TMS platforms offering enhanced features for carbon tracking and greener transportation options. These advancements position freight forwarders at the forefront of digital transformation, driving their accelerated adoption of modern TMS solutions and supporting robust growth in the forecast period.

Solution segment is expected to contribute to the largest market share during the forecast period

The solutions segment is experiencing rapid growth, driven by the acceleration of digital transformation and evolving logistics demands. Innovative TMS solutions now offer advanced features such as real-time shipment tracking, AI-powered route optimization, and seamless integration with enterprise resource planning (ERP) and warehouse management systems (WMS). Recent developments include cloud-native architectures, mobile accessibility, and predictive analytics that empower businesses with actionable insights and increased supply chain visibility.

The adoption of Internet of Things (IoT) sensors, robust data analytics, and automation technologies is enabling smarter decision-making, enhanced operational efficiency, and lower transportation costs. Increasing e-commerce activity, rising customer expectations for speed and transparency, and greater emphasis on sustainability are fueling demand for modern TMS solutions. As companies strive to improve delivery reliability and gain strategic advantages, these innovative solutions continue to transform logistics operations and drive wider adoption across the transportation and supply chain industry.

Asia Pacific region is projected to register the highest CAGR during the forecast period

The Asia Pacific region is rapidly solidifying its position as the global growth leader in the transportation management system (TMS) market, driven by a convergence of regulatory advancements, ambitious government initiatives, and local innovation in digital logistics solutions. China, India, Japan, and Australia are prioritizing logistics modernization through progressive data transparency laws, environmental mandates, and smart supply chain incentives. Regulatory breakthroughs, such as Singapore’s advanced environmental regulations and Vietnam’s digital energy management reforms, are directly supporting logistics providers in optimizing fleet operations and reducing emissions.

Across the region, governments are actively investing in digital transport corridors, next-generation road and rail infrastructure, and technology subsidies to fast-track TMS adoption. The business landscape is further energized by a surge in domestic M&A activity, with local TMS vendors in India and Japan launching AI-powered, cloud-native platforms tailored for the region’s booming e-commerce and urban logistics needs. These developments, underscored by robust partnerships between regional technology firms and logistics operators, are accelerating digital transformation and positioning Asia Pacific as the fastest-expanding TMS market globally, driven by an environment conducive to innovation, connectivity, and supply chain sustainability.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=232446179

Unique Features in the Transportation Management System Market

Modern TMS platforms offer end-to-end, real-time visibility into shipments across modes and carriers — GPS tracking, EDI/API status updates, and telematics streams — enabling operations teams to see location, estimated time of arrival, and exceptions as they happen. This visibility reduces dwell time, improves exception handling, and supports proactive customer communications.

Advanced route optimization engines calculate efficient multi-stop routes by balancing distance, time windows, vehicle capacity, traffic, and service constraints. These engines use heuristics and sometimes machine learning to re-optimize on the fly, driving lower miles, reduced fuel spend, and higher driver utilization — a major differentiator for high-density last-mile and LTL networks.

Leading TMS solutions natively handle multi-modal shipments (truck, rail, ocean, air) and intermodal transfers, coordinating pickup, handoffs, and documentation across carriers. This capability lets shippers optimize cost vs. transit time, consolidate loads across modes, and manage complex cross-border or global logistics flows from a single pane of glass.

Unique TMS systems combine real-time rate shopping across contracted carriers, spot market rates, and freight marketplaces, often using rules and historical performance to select the best option. Dynamic procurement features automate tendering, manage contract compliance, and enable immediate comparison between cost, transit time, and carrier KPIs.

Major Highlights of the Transportation Management System Market

The TMS market is witnessing strong growth, largely fueled by the exponential rise of e-commerce and omnichannel retail. Increasing online orders, faster delivery expectations, and complex fulfillment models are compelling businesses to adopt TMS solutions for cost efficiency and timely delivery.

A major highlight of the TMS market is the rapid adoption of cloud-based and SaaS platforms. Enterprises prefer subscription models for scalability, faster implementation, lower upfront costs, and seamless integration with ERP, WMS, and other enterprise systems.

Advanced technologies such as artificial intelligence (AI) and machine learning (ML) are increasingly embedded in TMS solutions. These enhance route optimization, predictive ETAs, demand forecasting, and anomaly detection — transforming TMS from a transactional tool into a strategic intelligence platform.

The demand for real-time shipment visibility across modes and geographies is driving the adoption of TMS platforms integrated with IoT, telematics, and GPS tracking. Shippers and customers alike expect proactive alerts, automated exception handling, and improved end-to-end transparency.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=232446179

Top Companies in the Transportation Management System Market

The major vendors dominating the transportation management system market include Oracle (US), SAP (Germany), Manhattan Associates (US), C.H. Robinson (US), and Trimble (US). These players have adopted various growth strategies, such as partnerships, business expansions, agreements, collaborations, and new product launches, to expand their transportation management system presence.

Oracle

Oracle delivers a comprehensive suite of transportation-related products, services, and solutions organized into three primary segments: cloud & license, hardware, and services. The cloud and license division provides robust infrastructure technologies and applications through Oracle Cloud, on-premises licenses, and associated support. The hardware segment features engineered systems, servers, storage, and hardware tailored for industry-specific requirements. The services arm offers IT and consulting solutions, spanning application support, technology services, and regulatory compliance. Oracle also manages cloud-based services, software & hardware management, and security, ensuring holistic lifecycle support.

SAP

SAP is a global leader in enterprise solutions, offering a robust portfolio of applications, technology services, and advanced analytics that cater to various industries such as education, finance, healthcare, manufacturing, public safety, transportation, and retail. By leveraging cutting-edge technologies, including machine learning, the Internet of Things (IoT), and advanced analytics, SAP provides clients with dynamic business intelligence through its flexible software licenses, SAP Cloud Platform, and comprehensive subscription-based cloud applications. The company delivers intelligent solutions for ERP, digital supply chain management, and human experience management, enabling organizations to optimize operations, enhance customer experience, and ensure competitive agility.

Manhattan Associates

Manhattan Associates is a prominent player in the Transportation Management System market, offering advanced solutions through its Manhattan Active® Transportation Management platform. The company focuses on optimizing freight movements, reducing transportation costs, and improving service levels across global supply chains. Its TMS integrates AI, machine learning, and real-time visibility, empowering shippers with predictive insights and automated decision-making. Manhattan’s cloud-native solutions cater to industries like retail, manufacturing, and logistics, supporting both inbound and outbound transportation operations at scale.

C.H. Robinson

C.H. Robinson, a global logistics powerhouse, leverages its proprietary Navisphere® platform to deliver robust Transportation Management System capabilities. The platform connects shippers and carriers with real-time data, predictive analytics, and end-to-end visibility to streamline supply chain operations. By combining its extensive logistics network with digital innovation, C.H. Robinson enables companies to optimize routing, improve delivery performance, and manage transportation spend efficiently. Its TMS is particularly valued for multimodal logistics management and strong customer support.

Trimble Inc.

Trimble is a key player in the TMS market, providing comprehensive transportation and logistics solutions via its Trimble Transportation division. Its TMS software helps carriers, brokers, and shippers manage freight operations with tools for load planning, route optimization, compliance, and analytics. Trimble’s platform is known for integrating telematics, mobile applications, and automation to enhance visibility, reduce costs, and drive operational efficiency. With a focus on the digital supply chain, Trimble supports both asset-based and non-asset-based logistics operations across North America and beyond.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/transportation-management-market-232446179.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Transportation Management System Market Growth Drivers, Emerging Trends, Opportunities, Key Segments, Recent Development, and Future Outlook To 2030